- Home
- / UK & Ireland solutions /
- UK & Ireland Access Consultancy
Uk and Ireland access consultancy
At Kintiga in the UK and Ireland, we’re more than consultants—we’re your dedicated partners in navigating the intricacies of market access across Europe. Our team delivers bespoke, region-specific strategies that support your product’s journey from early development through long-term market presence. By working side-by-side with your team, we help shape effective strategies that are are not only actionable but built for success in a dynamic European landscape.
A Comprehensive Patient-Centred Approach
Our expert team offers a broad range of specialist support. Helping you to bring innovative therapies to patients across in the UK, Ireland and across Europe demands a deep understanding of the distinct local regulatory and reimbursement frameworks. At Kintiga, we specialise in guiding you through the complexities of market access employing local expertise with a global perspective. Our experts in the BeNeLux region can collaborate closely with your team to develop integrated strategies that align with national policies and payer expectations. Whether you’re preparing to launch a novel treatment, managing multiple indications, or responding to shifting healthcare landscapes or thinking of acquiring a new product for your pipeline , we bring together insights from pricing & reimbursement, regulatory and medical affairs, HEOR, clinical development, and commercial planning. From early development through post-launch optimisation, Kintiga ensures your product is positioned for success in Europe and beyond.
Kintiga understands the challenges facing life science companies in bringing their products to market. With decades of experience, we know how to navigate and overcome the many obstacles you might be facing.
Our services
- Early development and strategic planning
- Market Access & Pricing Strategy
- Health Economics and Outcomes Research and de novo modelling
- Landscape analysis and go-to-market planning
- Integrated market access strategy across major and emerging EU markets
- Product positioning and scientific value communications
- Policy & Public Affairs
- Lifecycle access planning, launch and indication sequencing
- Cross-functional alignment to support internal and external stakeholder engagement
- Integrated evidence strategy
- Customer engagement strategy and support
- Value propositions
- Global Value Dossiers
- Core Reimbursement Dossiers
- Objection Handlers
- AMCP Dossiers
- PIM and EAMS applications
- HTA and reimbursement submissions
- Study reports
- Stakeholder communication tools
- Evidence Identification & Synthesis
- Early Scientific Advice
- Systematic Literature Reviews
- Targeted Literature Reviews
- Scoping Reviews
- Publications / Manuscripts
- Conference Presentations & Posters
- Expert opinion via structured (utility elicitation, Delphi panels) and unstructured methodologies
- NMAs Feasibility & Analysis
- MAICs Feasibility & Analysis
- PIM / EAMS / ILAP
- Early Access Programmes
- HTA Landscape & Risk Mitigation
- HTA Strategic Planning & Navigation
- NICE appraisal submissions including STA, HST and the various proportionate approaches
- SMC submissions
- AWMSG Submissions
- NCPE RR & Full HTA Submissions
- European HTA Submissions
- Early HTA Economic Modelling
- Early TTP Strategy Modelling
- Core CE & BIM
- Design & Build Field-Based Value Tools
- Model QC and Validation
- Adaptation Survival & Surrogate End Point Modelling
- Strategy Landscaping
- TPP Testing
- Evidence Generation
- Planning & Delivery
- Value Messaging & Communication
- Advisory Boards
- Coalition Development
- Clinical Engagement & Patient Advocacy Consensus Statement Development
Delivering impact through excellence
Results speak louder than words. At Kintiga, our track record of success demonstrates our ability to deliver impactful market access strategies that align with your ambitions.
Let’s have a chat
We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.
Julia Sus
Director, Market Access, UK
Claire Blaney
Director Market Access & Pricing Strategy Ireland
Priscila Mazzola
Director, Head of Value Communication in Value Communication
Ben Hendry
Director, Business Development UK & Ireland
Featured case studies
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
PMI Pharma Summit
NICE Conference 2026
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Our expertise:
UK and Ireland Access Consultancy
Our UK and Ireland team provide tailored strategic guidance and end-to-end support across development, launch, and lifecycle management, aligned with NICE, SMC, AWMSG, and NCPE pathways and evolving HTA expectations.
UK and Ireland Market Access Pathways
Success starts with a clear launch pathway. Kintiga offers UK and Ireland expertise, supporting NICE, SMC, AWMSG, and NCPE submissions with strong evidence alignment, payer negotiation, and stakeholder engagement to drive positive outcomes.
EU HTA Strategy Support
With extensive NICE submission experience, Kintiga is well positioned to support Joint Clinical Assessments, offering integrated solutions from JSC advice to JCA reporting for successful EU HTA outcomes.
Health Economics and Outcomes Research
Our Health Economists build and adapt economic models for the UK and Ireland, integrating local data, comparators, and care pathways. We also develop early pricing and access models to guide investment and evidence strategies aligned with payer expectations.
Pricing Strategy
Kintiga analyses pricing landscapes and benchmarks competitors to shape early pricing strategies. We integrate value messaging and design long-term frameworks like risk-sharing and managed entry agreements to ensure sustainable UK and Ireland market access.
Policy and Systems Navigation
Kintiga monitors policy changes across NHSE, DoH, HSE, and regional bodies to assess their impact on your product. We provide strategic engagement with key institutions and support managed access, conditional reimbursement, and policy initiatives to optimise market entry and sustainability.
Contact us
Ready to unlock your product’s potential in Europe’s complex healthcare landscape? Contact Kintiga today to discover how our market access strategy expertise can drive measurable impact for your product.
